Creative Biolabs Unveils Enhanced mRNA Immunotherapy Platform for Preclinical Innovation

Creative Biolabs is advancing preclinical research with its expanded mRNA immunotherapy development platform, offering a versatile approach distinct from conventional protein-based methods. This platform provides a temporary molecular blueprint for cells to produce selected antigens, cytokines, antibodies, or immune-regulating proteins. Its transient, non-integrating mechanism makes mRNA an attractive modality for researchers investigating immune activation, tumor antigen presentation, and targeted protein expression. The service focuses on customized mRNA design, optimization, delivery strategy development, and validation support for a wide range of research applications, including tumor-associated antigens, immune modulators, and mRNA-encoded functional proteins.

Addressing a key challenge in mRNA immunotherapy, Creative Biolabs offers specialized polymer vector development services. These polymer-based delivery systems, such as polyplex and micelleplex platforms, are meticulously tailored to enhance mRNA stability, cellular uptake, and endosomal escape while managing formulation-related toxicity and stability. Beyond delivery, the platform also provides a CLIP-Seq RNA-protein interaction analysis service, enabling transcriptome-wide investigation of RNA-protein interactions. This high-resolution mapping and bioinformatics interpretation help researchers understand regulatory elements and post-transcriptional mechanisms crucial for optimizing mRNA design and immune response.

A promising direction within the field is antibody-encoding mRNA, which enables cells to transiently express antibody proteins or fragments, bypassing traditional recombinant protein manufacturing. Creative Biolabs supplies antibody mRNA products with diverse modification strategies, cap structures, and poly(A) tail designs, supporting studies in antibody mechanism research and exploratory therapeutic development. This expansion signifies a shift towards programmable platforms adaptable to antigen selection, expression duration, and immune mechanisms, offering preclinical investigators opportunities to evaluate personalized neoantigen strategies, mRNA-encoded cytokines, and combination approaches with other immunotherapy modalities.